Pharmaceutical News

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe...

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Twenty-five years after the World Trade Center terror attack on September 11, 2001, physicians and patients gathered at Northwell’s Long Island Jewish (LIJ) Medical Center to commemorate the grim anniversary and to sound the alarm to an ongoing health crisis. The past is prologue for a slow-motion health disaster as cancer cases have exploded among some of the approximately 145,000 people currently enrolled in the World Trade Center (WTC) Health Program, wh...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.Interested parties can access the live webcas...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 86,500 shares of common stock to four new employees under the Co...

NEW YORK--(BUSINESS WIRE)--Forus, the AI network accelerating medicine, today announced $150 million in Series C financing at a $3 billion valuation, tripling its valuation just months after announcing its Series B and bringing total funding to more than $300 million. The round was led by Bain Capital Ventures, an investor in Forus since its seed round. Every existing institutional investor is reinvesting, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Hum...

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healthcare Conference in Boston, MA Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York City Wednesday, September 16, 2026, at 10:45 a.m. Eastern Time Bank of America Global Healthcare Conference in London, UK Tuesday, September 22, 2026, at 6:45 a....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines...

BOSTON--(BUSINESS WIRE)--Leveragen, Inc., a Boston-based biotechnology company advancing in vivo antibody discovery, today announced the grant of Australian Patent No. 2022271276 on September 3, 2026. Titled "Engineered Non-Human Animals for Producing Antibodies," the patent covers core innovations underlying the Singularity Platform. The grant follows the company's February 25, 2026, announcement of Japan Patent No. JP7799706, extending protection for its proprietary approach to single-domain...

LOS ANGELES--(BUSINESS WIRE)--HCR™ Gold IF on the ONCORE Pro X enables automated multiplex protein imaging with off-the-shelf primary antibodies....

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The...